4D Molecular Therapeutics, Inc. (FDMT - Free Report) shares rallied 16% in the last trading session to close at $8.93. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 14.2% loss over the past four weeks.
The stock's surge can be attributed to the investors’ optimism around the company's third-quarter earnings, to be released soon. The optimism is being driven by the drug/biotech sector’s growth in the ongoing year.
This company is expected to post quarterly loss of $0.85 per share in its upcoming report, which represents a year-over-year change of -3.7%. Revenues are expected to be $1.7 million, up 24.2% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For 4D Molecular Therapeutics, Inc., the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on FDMT going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
4D Molecular Therapeutics, Inc. belongs to the Zacks Medical - Drugs industry. Another stock from the same industry, Xencor (XNCR - Free Report) , closed the last trading session 0.6% lower at $28.11. Over the past month, XNCR has returned 7%.
For Xencor, the consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.77. This represents a change of -11.6% from what the company reported a year ago. Xencor currently has a Zacks Rank of #3 (Hold).
4 Oil Stocks with Massive Upsides
Global demand for oil is through the roof... and oil producers are struggling to keep up. So even though oil prices are well off their recent highs, you can expect big profits from the companies that supply the world with "black gold."
Zacks Investment Research has just released an urgent special report to help you bank on this trend.
In Oil Market on Fire, you'll discover 4 unexpected oil and gas stocks positioned for big gains in the coming weeks and months. You don't want to miss these recommendations.
Download your free report now to see them.
4D Molecular Therapeutics, Inc. (FDMT - Free Report) shares rallied 16% in the last trading session to close at $8.93. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 14.2% loss over the past four weeks.
The stock's surge can be attributed to the investors’ optimism around the company's third-quarter earnings, to be released soon. The optimism is being driven by the drug/biotech sector’s growth in the ongoing year.
This company is expected to post quarterly loss of $0.85 per share in its upcoming report, which represents a year-over-year change of -3.7%. Revenues are expected to be $1.7 million, up 24.2% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For 4D Molecular Therapeutics, Inc., the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on FDMT going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
4D Molecular Therapeutics, Inc. belongs to the Zacks Medical - Drugs industry. Another stock from the same industry, Xencor (XNCR - Free Report) , closed the last trading session 0.6% lower at $28.11. Over the past month, XNCR has returned 7%.
For Xencor, the consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.77. This represents a change of -11.6% from what the company reported a year ago. Xencor currently has a Zacks Rank of #3 (Hold).
4 Oil Stocks with Massive Upsides
Global demand for oil is through the roof... and oil producers are struggling to keep up. So even though oil prices are well off their recent highs, you can expect big profits from the companies that supply the world with "black gold."
Zacks Investment Research has just released an urgent special report to help you bank on this trend.
In Oil Market on Fire, you'll discover 4 unexpected oil and gas stocks positioned for big gains in the coming weeks and months. You don't want to miss these recommendations.
Download your free report now to see them.
Get the latest research report on XNCR - FREE
Get the latest research report on FDMT - FREE